Objectives: Demonstration of MN PMP RxSentry Reports from workgroups

Similar documents
K-TRACS: Review of Program Data and a Qualitative Assessment Study

South Carolina Reporting & Identification Prescription Tracking System (SCRIPTS)

Prescription Monitoring Programs - Legislative Trends and Model Law Revision

Advancing MN Pharmacy 2016 Advocacy Accomplishments & 2017 Plans

NATIONAL ASSOCIATION FOR STATE CONTROLLED SUBSTANCES AUTHORITIES (NASCSA) MODEL PRESCRIPTION MONITORING PROGRAM (PMP) ACT (2016) COMMENT

Prescription Drug Monitoring Program (PDMP)

Georgia DPH. Prescription Title Drug Heading Monitoring Program Program. Sheila Pierce April 2018

Prescription Drug Monitoring Program (PDMP) LOUISIANA. Information contained in this presentation is accurate as of September 2017

Maine Chronic Pain Collaborative 2 (ME CPC2) Chronic Pain Management Change Package for Primary Care Practices

Massachusetts. Contact Information. State Registrant Totals and Population. PDMP name: MA Prescription Monitoring Program

Prescription Drug Monitoring Program (PDMP)

Colorado. Contact Information

Oklahoma. Contact Information. Office: Fax: Statistics

PRESCRIBING IN NEVADA

Legal Issues in Managing Opioid Abuse. Gwen Dayton, JD

New Mexico. Contact Information. State Registrant Totals and Population. PDMP name: NM PMP

District of Columbia Prescription Drug Monitoring Program

Role of e-prescribing in Preventing Opioid Abuse

Nevada. Contact Information. State Registrant Totals and Population

Tennessee. Tennessee Department of Health, Tennessee Board of Pharmacy Pharmacy Board

Tennessee. Contact Information. State Registrant Totals and Population. PDMP name: CSMD

MINNESOTA BOARD OF PHARMACY

Final Report. HealthPartners, Inc. And Group Health, Inc. Quality Assurance Examination

Prescription Monitoring Program State Profiles - Illinois

Mississippi. Contact Information. State Registrant Totals and Population

Prescriber Use of the PDMP: A Statewide Survey and Multistate Focus Groups

States that Allow Prescribers and/or Dispensers to Appoint a Delegate to Access the PMP

National Association of Boards of Pharmacy PMP Interconnect NABP

Ohio. Contact Information. State Registrant Totals and Population

Prescription Monitoring Program NL. Information for Prescribers and Dispensers

Pharmacy Pain Management Protocol Pharmacy Policy and Protocol

Prescription Drug Monitoring Program (PDMP)

Puerto Rico. Contact Information. State Registrant Totals and Population. PDMP name: PR PDMP

Statutes and Rules Updates Presented by: Kirk E. Masten, D.O. President, Medical Licensing Board of Indiana

Medication Assisted Treatment for Opioid Use Disorders Reporting Requirements

The Consistent Care Program Wednesday January 14, 2008

Alaska. Contact Information. State Registrant Totals and Population. PDMP name: AKPDMP

Duplicate Prescription Pad Disposal Policy and Guidelines

Final Report. UCare Minnesota 2005

Prescription Monitoring Program:

PRESCRIPTION MONITORING PROGRAM STATE PROFILES TENNESSEE

Understanding the Grievances and Appeals Process for Medicaid Enrollees

STATE OF TEXAS TEXAS STATE BOARD OF PHARMACY

ROTATION DESCRIPTION

2017 ASAP MIDYEAR CONFERENCE THE FUTURE OF PRESCRIPTION DRUG MONITORING PROGRAMS (PMPS): HIGHLIGHTS OF 2017 STATE BILLS JUNE 22, 2017 SHERRY L.

Michigan. Contact Information. State Registrant Totals and Population. PDMP name: MAPS

Executive, Legislative & Regulatory 2018 AGENDA. unitypoint.org/govaffairs

Prescription Monitoring Program State Profiles - Michigan

Prescription Monitoring Program State Profiles - Pennsylvania

Alabama. Prescribing and Dispensing Profile. Research current through November 2015.

Frequently Asked Questions MN Prescription Monitoring Program (PMP)

Mandatory Electronic Prescribing in NYS

Christopher W. Shanahan, MD, MPH, FACP

Final Report. PrimeWest Health System

SENATE, No STATE OF NEW JERSEY. 216th LEGISLATURE INTRODUCED APRIL 28, 2014

The Wisconsin epdmp:

CE/CME Evaluation & Credit Claim Form TITLE OF ACTIVITY: Prescribing Practices of Controlled Substance

North Carolina. Contact Information. State Registrant Totals and Population. PDMP region: PDMP name: Agency responsible:

EVOLENT HEALTH, LLC. Asthma Program Description 2018

Georgia Osteopathic Medical Association. Barby Simmons, DO John Downey, DO Georgia Composite Medical Board

Kentucky. Kentucky Cabinet for Health and Family Services Office of Inspector General

PROVIDER APPEALS PROCEDURE

States that Allow Prescribers and/or Dispensers to Appoint a Delegate to Access the PMP

Evidence-Based Practices to Optimize Prescriber Use of PDMPs

Emergency Rooms and Medical Necessity

PRESCRIPTION MONITORING PROGRAM STATE PROFILES MASSACHUSETTS

Report of the Task Force on Prescription Monitoring Program Standards

GOALS. I. Monitoring the quality of health care for safety, effectiveness and efficiency and seek opportunities for improvement

BEFORE THE NORTH CAROLINA MEDICAL BOARD ) ) ) ) ) This matter is before the North Carolina Medical Board

Types of Authorized Recipients Probation/Parole Officers or the Department of Corrections

Mid-Atlantic Legislative/Regulatory June 2018 Update

Policy Number: Title: Abstract Purpose: Policy Detail:

Prescription Monitoring Program State Profiles - California

PROPOSED REGULATION OF THE STATE BOARD OF OSTEOPATHIC MEDICINE. LCB File No. R069-16

Pharmacy Law Update for Pharmacists & Technicians October 1, 2017 Greg Baran, B.S., Pharm., M.A.

PMIX ADVANCING PMP DATA SHARING THROUGH STANDARDIZATION AND INNOVATION CARL FLANSBAUM, DIRECTOR, NEW MEXICO PMP CO-CHAIR PMIX WORKING GROUP

Medicare Advantage and Part D Fraud, Waste and Abuse Compliance Training 2015

Prescription Monitoring Program State Profiles - Kentucky

Steps Taken to Combat the Opiate Epidemic Through Legal And Technological Channels. Nick Snyder, Esq.

BJA COAP Category 5 Grantee Webinar Thursday, June 21, 2018

2016 Complex Case Management. Program Evaluation. Our mission is to improve the health and quality of life of our members

RULES OF DEPARTMENT OF HEALTH DIVISION OF PAIN MANAGEMENT CLINICS CHAPTER PAIN MANAGEMENT CLINICS TABLE OF CONTENTS

Request for Proposal Pain Management Center of Excellence

Prescription Monitoring Program State Profiles - Texas

POLICY AND PROCEDURE DEPARTMENT: Pharmacy Operations

EVOLENT HEALTH, LLC. Asthma Program Description 2017

Pharmaceutical Diversion Prevention, Detection and Incident Response

This report is a summary of the November 2015 Behavioral Health Stakeholder s Summit that was held in Fargo.

Committee on Pharmacy Practice

*HMOs of BLUE CROSS AND BLUE SHIELD OF ILLINOIS Utilization Management and Care Coordination Plan

Legal Issues You Should Know April 25, 2018 In-House Counsel Conference

Behavioral Health Services

What Does it Mean for Physicians, Hospitals. Denny Maher, General Counsel, WSMA Zosia Stanley, Policy Director, Access, WSHA

Table of Contents. Introduction: Basis, purpose and statutory provision

UTILIZATION MANAGEMENT PROGRAM DESCRIPTION MEDICAL ASSOCIATES HEALTH PLANS 2016

Prescriptive Authority Agreement Advanced Practice Registered Nurses, and Physician Assistants

Interim Commissioner Lauren A. Smith and Members of the Public Health Council

2015 Annual Convention

The Challenges of Interstate Data Sharing

Getting Started with OIG Compliance

Transcription:

MN Prescription Monitoring Program Advisory Task Force Meeting Monday, September 29, 2014, 1:30pm-3:00pm University Park Plaza, 2829 University Ave SE, Conference Room A, Minneapolis, MN 55414 Objectives: Demonstration of MN PMP RxSentry Reports from workgroups ATTENDEES: Committee Members Present: Kevin Evenson, Connie Jacobs, Neal Benjamin, Alfred Anderson, Julie Sabo, Julia Wilson, David Thorson, Betty Johnson, Mary Benbenek, Michelle Aytay for Jeff Lindoo, Richard Neumeister, Carol Falkowski, Lindsey Thomas Absent: Diane Rydrch, Connie Jacobs (excused), Michelle Shih-Ming Falk, Ruth Grendahl, Collin Arnett, Carmelo Cinqueonce Board of Pharmacy Staff: Barbara A. Carter, Cody Wiberg, Judy Little I. Call to Order, Welcome & Introductions Overview of the objectives for today s meeting Introduction of Committee Members II. Current PMP Activities Replacement of PMP Coordinator Status of new position Interviews for both positions will be conducted during the period 9/30/14-10/8/14 III. Old Business Action Items from 9/29/14 PMP-ATF meeting 1. Number of search warrants (during period 1/1/14-6/30/14) and from which agencies they are coming from? 229 Search warrants Specific Agencies are unknown as a search warrant does not specify an agency, only the county of issuance. Hennepin-205 Anoka-23 Wright-1

2. # of prescriptions that were in the database last year at this time vs. the number prescriptions that are in the database currently? On 9/1/2013 6,816,699 On 9/1/2014 6,585406 6/2014 569,545 vs. 8/2014 800,460-substantial increase, may be due to reporting of tramadol and butalbital, along with removal of certain exemptions from reporting. 3. # of unique individuals currently in the database? 1,565,039 Comparable to year around this same timeframe 4. Volume of queries going through PMPi and where they are initiated? Summary: July 2014 August 2014 Participating 18 19 States Queries from 14,699 with 15,480 with other states Queries to other states 1,218 matches 20,336 with 1,107 matches 1,305 matches 31,699 with 1,228 matches IV. Demonstration of the MN PMP RxSentry system A demonstration in the use of the MN PMP RxSentry system was given. Areas covered: o Log in o MN patient search& generating report o Multi-state patient search& generating report o Conducting a search for query activity-both own activity and delegate activity o Conducting a Prescriber s Search by DEA query (shows prescriptions associated with the prescriber who is logged into the system) V. Workgroup Activities Task force members were provided several handouts that workgroup members provided during the workgroup meetings. None of these handouts was reviewed as they were provided as a courtesy to those not on the various workgroups. Reports from workgroups i. Required Use Workgroup Members: Carol Falkowski, Kevin Evenson, Jeff Lindoo, David Thorson, Betty Johnson, Rich Neumeister Several handouts were provided to the members at this meeting as well as after the meeting. These was much discussion during the meeting and

no consensus was reached as to whether or not there should be required/mandatory use of the MN PMP by prescribers and pharmacists. Recommendations varied and included: 1. Rather than mandatory use, guidelines should be developed by a multidisciplinary group such as Institute for Clinical System Improvements (ICSI) and those guidelines should also include a quality measure to show how the guidelines are being used and how effective they are. 2. Some workgroup members were comfortable with mandatory checking in certain situations such as opioid prescriptions out of the ER or Urgent Care, all new opioid prescriptions from a new provider, or yearly for those on chronic scripts. 3. Some felt mandatory use should be required by both the prescriber and the pharmacist for all opioid prescriptions. 4. Some felt mandatory use should be required by both the prescriber and the pharmacist anytime a new prescription for any controlled substance is written. 5. Dr Thorson indicated that he was willing to bring back to MMA any ideas from the workgroup and thinks he could get support for selective mandates with the understanding that work towards a hardwired solution, like they have for drug/drug interactions, can be implemented within the next 3 years and that the HIPAA concerns (keeping a copy of the PMP information as part of the medical record) can be addressed. This workgroup will meet again in October. ii. Identification of Inappropriate Prescribing Workgroup Members: Neal Benjamin, Julia Wilson, Alfred Anderson, Connie Jacobs, Julie Sabo and Rich Neumeister There was much discussion during the workgroup meeting and the following are some initial ideas that need to be further discussed: 1. Communications with prescribers is important if we are to ensure there is no impact on appropriate prescribing. There may be a need to reeducate prescribers on controlled substance prescribing. 2. If the Boards are to have access to prescribing data there need to be good oversight to prevent fishing expeditions What triggers a request for data from the MN PMP? A bona fide complaint investigation. 3. The current process in place for investigating a complaint related to inappropriate prescribing is not expeditious; getting information from the PMP would move things along with resolution much sooner. 4. The workgroup has asked that additional information be collected from the Boards as follows: a. How necessary is it for the boards to have access to prescribing history? i. Would it assist in expediting the investigation process?

b. How many complaints related to overprescribing during the past 2 years? i. Of those complaints, how many were actually disciplined? c. How important is it for the board to be able to access the prescriber s individual prescription history as part of an investigation (without requiring consent)? 5. It was recommended that we stay away from proactively searching the database to identify potential inappropriate prescribing patterns as it may cause a chilling effect on prescribing. Additionally, having prescription data alone and no supporting diagnosis information or detailed patient information makes it virtually impossible to determine, based on the PMP data alone, that the prescribing may be inappropriate. A representative from DHS spoke to the workgroup and indicated that DHS Medicaid patient database does reveal outliers and that if deemed appropriate will file a complaint with the board. Their data is much more comprehensive than the PMP data in that there are diagnosis codes and other medical information available to them. It was pointed out that there are two states whose law states that they are required to report inappropriate prescribing to the board and in both cases, law enforcement as well. Those two states are MS and NV. Most other states allow the PMP to report to the boards. The workgroup will meet again to refine its recommendations.

iii. Encouraging Access to Appropriate Treatment Workgroup Members: Betty Johnson and Kevin Evenson There was much discussion during the workgroup meeting and the following are some initial ideas as to how to encourage access to treatment using the PMP: 1. Education in how to recognize addiction 2. Add resources to the MN PMP website for both the practitioner and the patient, such as a link to the SAMSHA s Behavioral Health Treatment Services Locator. 3. Notification to all system users of the new updated resources pages 4. Encouraging practitioners to print off information for the patient or help the patient call to arrange for assistance. 5. Market the delegate account option to encourage system use. 6. Use of Screening, Brief Intervention and Referral to Treatment (SBIRT) as a means of early identification of substance abuse disorders The workgroup will meet again to fine tune its recommendations. VI. Next Steps, Announcements & Wrap-up VII. Adjourn: Meeting was adjourned at 3:45pm. Next meeting is scheduled for Tuesday, October 28, 2014.